{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T17:43:03Z","timestamp":1782495783460,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) enhance antitumor immunity by blocking inhibitory immune signals, but can lead to immune-related adverse events (irAEs). Therefore, effective management of irAEs is crucial during ICI therapy. We report the case of a 50-year-old man who was referred to our department due to cough and abnormal chest shadows. He was diagnosed with hypopharyngeal cancer, and underwent chemoradiotherapy, resulting in complete remission. However, metastatic tumors were detected, and partial lung resection was performed. After one-year, new metastatic tumors and pleural dissemination were identified. Therefore, treatment with pembrolizumab was initiated. After the treatment with pembrolizumab, chest imaging revealed ground-glass opacity (GGO). Laboratory tests showed elevated eosinophils, and fractional exhaled nitric oxide (FeNO). The findings of bronchoscopy revealed eosinophilic infiltration and intraluminal fibrosis, consistent with chronic eosinophilic pneumonia (EP). Based on these findings, he was diagnosed with pembrolizumab-induced chronic EP. Pembrolizumab was temporarily discontinued, and oral corticosteroids (OCS) were initiated. After the treatment of OCS, his symptoms and GGO were dramatically improved. Subsequently, pembrolizumab was resumed, and the hypopharyngeal cancer remains stable without recurrence of EP. This report presents the first pembrolizumab-induced chronic EP during treatment for hypopharyngeal cancer. The chronic EP was effectively managed with systemic corticosteroid therapy. Furthermore, pembrolizumab was resumed with close monitoring of blood eosinophil counts and FeNO levels, without worsening of EP. The results of the current case suggest that ICI-induced chronic EP is manageable, and in cases where ICI therapy exhibits significant efficacy against cancer, its treatment may be continued with careful monitoring of these parameters.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1615531","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:10:35Z","timestamp":1753157435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Successful management of chronic eosinophilic pneumonia triggered by immune checkpoint inhibitor: a case report and literature review"],"prefix":"10.3389","volume":"16","author":[{"given":"Yasuhito","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junpei","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masakazu","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Rikimaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kumanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryutaro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Kazama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Harigane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riko","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Tomita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsumi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Umeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takefumi","family":"Nikaido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenya","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Tanino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Murono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.175561","article-title":"Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: A real-world study from 2014 to 2022 based on faers databases","volume":"946","author":"Cui","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.06.021","article-title":"Immune checkpoints in the tumor microenvironment","volume":"65","author":"Toor","year":"2020","journal-title":"Semin Cancer Biol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"Itc17","DOI":"10.7326\/aitc202402200","article-title":"Immune-related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann Intern Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2017.1372421","article-title":"Autoimmune diseases induced by biological agents. A review of 12,731 cases (Biogeas registry)","volume":"16","author":"P\u00e9rez-De-Lis","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.alit.2019.05.006","article-title":"Eosinophilic pneumonia: A review of the previous literature, causes, diagnosis, and management","volume":"68","author":"Suzuki","year":"2019","journal-title":"Allergol Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2018.03.011","article-title":"Eosinophilic pneumonias","volume":"6","author":"Allen","year":"2018","journal-title":"J Allergy Clin Immunol In Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.anl.2023.07.003","article-title":"Summary of Japanese clinical practice guidelines for head and neck cancer - 2022 update edited by the Japan society for head and neck cancer","volume":"51","author":"Homma","year":"2024","journal-title":"Auris Nasus Larynx"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (Keynote-048): A randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1355247","article-title":"Acute and chronic eosinophilic pneumonia: an overview","volume":"11","author":"Carbone","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B11","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/j.1440-1843.2005.00648.x","article-title":"Clinicopathological differences between acute and chronic eosinophilic pneumonia","volume":"10","author":"Mochimaru","year":"2005","journal-title":"Respirology (Carlton Vic)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/iid3.238","article-title":"A potential mechanism of the onset of acute eosinophilic pneumonia triggered by an anti-pd-1 immune checkpoint antibody in a lung cancer patient","volume":"7","author":"Jodai","year":"2019","journal-title":"Immun Inflammation Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.15030","article-title":"Eosinophilic pneumonia and esophagitis in a patient with Malignant melanoma treated with nivolumab","volume":"46","author":"Hattori","year":"2019","journal-title":"J Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13848","article-title":"Immune checkpoint inhibitors-induced eosinophilic pneumonia: A case report","volume":"12","author":"Hara","year":"2021","journal-title":"Thorac Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyab130","article-title":"Acute eosinophilic pneumonia after changing dosing schedule of nivolumab","volume":"51","author":"Shinada","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"B16","article-title":"A case of eosinophilic pneumonia after immune checkpoint inhibitor treatment following concurrent chemoradiotherapy","volume":"44","author":"Mouri","year":"2022","journal-title":"J Japan Soc Respir Endoscopy"},{"key":"B17","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2022.08.1023","article-title":"Eosinophilic pneumonia secondary to immune checkpoint inhibitor therapy with pembrolizumab","volume":"162","author":"Selvan","year":"2022","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1016\/j.chest.2024.06.1917","article-title":"A case of pembrolizumab-induced acute eosinophilic pneumonia","volume":"166","author":"Golden","year":"2024","journal-title":"Chest"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm-conference.2024.209.1","article-title":"Immune-checkpoint inhibitor-related eosinophilic pneumonia","author":"Clark","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"210277660","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur Respir J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.36416\/1806-3756\/e20240110","article-title":"Drug-induced lung disease: A narrative review","volume":"50","author":"Bridi","year":"2024","journal-title":"J Bras Pneumol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S136818","article-title":"Clinical features, diagnostic challenges, and management strategies in checkpoint inhibitor-related pneumonitis","volume":"9","author":"Chuzi","year":"2017","journal-title":"Cancer Manag Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.16.17315","article-title":"A review of clinical and imaging findings in eosinophilic lung diseases","volume":"208","author":"Bernheim","year":"2017","journal-title":"AJR Am J Roentgenol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e70679","DOI":"10.1002\/cam4.70679","article-title":"Exploring the dynamics of immune checkpoint inhibitor-induced eosinophilia in advanced\/metastatic melanoma: A comprehensive retrospective analysis","volume":"14","author":"Diamantopoulos","year":"2025","journal-title":"Cancer Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1165\/rcmb.2006-0419OC","article-title":"Measurement of il-13-induced inos-derived gas phase nitric oxide in human bronchial epithelial cells","volume":"37","author":"Suresh","year":"2007","journal-title":"Am J Respir Cell Mol Biol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-1303","article-title":"Fraction of exhaled nitric oxide in patients with acute eosinophilic pneumonia","volume":"141","author":"Lee","year":"2012","journal-title":"Chest"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1186\/1465-9921-12-81","article-title":"Increase of nitrosative stress in patients with eosinophilic pneumonia","volume":"12","author":"Furukawa","year":"2011","journal-title":"Respir Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.3390\/biom12101385","article-title":"Galectin-10 as a potential biomarker for eosinophilic diseases","volume":"12","author":"Tomizawa","year":"2022","journal-title":"Biomolecules"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1093\/annonc\/mdx455","article-title":"Nivolumab-induced asthma in a patient with non-small-cell lung cancer","volume":"28","author":"Maeno","year":"2017","journal-title":"Ann Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1333850","article-title":"The occurrence of asthma in an extensive-stage small-cell lung cancer patient after combination therapy with atezolizumab and anlotinib: A case report","volume":"15","author":"Deng","year":"2024","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e70022","DOI":"10.1002\/rcr2.70022","article-title":"Eosinophilic reactive airways disease after immune checkpoint inhibitor treatment","volume":"12","author":"Cordial","year":"2024","journal-title":"Respirol Case Rep"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","article-title":"Pd-1\/pd-L1 checkpoint inhibitors in tumor immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front Pharmacol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1038\/s41467-022-32899-5","article-title":"Pd-L2 controls peripherally induced regulatory T cells by maintaining metabolic activity and foxp3 stability","volume":"13","author":"Hurrell","year":"2022","journal-title":"Nat Commun"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/j.1398-9995.2010.02458.x","article-title":"Role of pd-L1 and pd-L2 in allergic diseases and asthma","volume":"66","author":"Singh","year":"2011","journal-title":"Allergy"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0601347103","article-title":"Regulation of T cell activation and tolerance by pdl2","volume":"103","author":"Zhang","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e1003215","DOI":"10.1371\/journal.ppat.1003215","article-title":"Th2 cell-intrinsic hypo-responsiveness determines susceptibility to helminth infection","volume":"9","author":"van der Werf","year":"2013","journal-title":"PloS Pathog"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/cea.13017","article-title":"Differential regulation of pd-1 and its ligands in allergic asthma","volume":"47","author":"Bratke","year":"2017","journal-title":"Clin Exp Allergy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1615531\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T04:10:36Z","timestamp":1753157436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1615531\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":38,"alternative-id":["10.3389\/fimmu.2025.1615531"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1615531","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"article-number":"1615531"}}